Intellia Therapeutics Inc (NTLA) Stock Price Up 2.8%
Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price rose 2.8% during mid-day trading on Friday . The company traded as high as $18.38 and last traded at $18.37, with a volume of 72,386 shares traded. The stock had previously closed at $17.87.
A number of research firms recently weighed in on NTLA. Jefferies Group raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Friday, August 5th. Leerink Swann began coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective on the stock. Credit Suisse Group AG started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective on the stock. Wedbush started coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, Zacks Investment Research lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $35.50.
The firm has a 50-day moving average of $19.43 and a 200-day moving average of $23.16. The firm’s market cap is $660.15 million.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.